REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/23/2026
Back to search
Official data from USPTO
EVOLVE BIOLOGICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
EVOLVE BIOLOGICS
ST13
US500000087671420Class
5, 37, 40, 41, 42
Filing
87671420
Registration
6297746
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
54
Latest update
03/24/2026
Trademark type
Word
Nice classes
5, 37, 40, 41, 42
Filing date
11/03/2017
Registration date
03/23/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/23/2021
Last transaction
03/24/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
03
Owner location
Mississauga, Ontario, CA
Examiner
MORENO, PAUL A
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Evolve Biologics Inc.
Therapure Biopharma Inc.
Representatives
Christopher J. Schulte MERCHANT & GOULD P.C.
Technical classification
Nice Classes
Class 5Class 37Class 40Class 41Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biologics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate for human clinical useplasma protein fractionsserum albuminimmunoglobulinscoagulation factorsantihemophilic factorsclotting factorsenzymescoenzymescoactivatorsinhibitorsstructural proteins; resinsfor medical usepolysaccharide beads cross-linked to ligands for capturing proteins from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate using chromatographic methods
Class 37
Construction of biotechbiopharmaceutical and plasma manufacturing facilities relevant to the manufacturing of biologics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate; consulting services concerning construction of biotech; Consulting services concerning building construction of biotech facilities
Class 40
Contract manufacturing services for others for biologics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate for research and developmentclinical use; consulting services concerning manufacturing of biologics
Class 41
Educational servicesdesigningarrangingconducting training programs for research and developmentmanufacturing of biologicsdesignconstructionuse of chromatography equipment
Class 42
Development of pharmaceutical preparations and medicinesdevelopment services for others for the capture of biologics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate for research and development; consulting services for others concerning the capture of biologics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate for research and developmentdesign and construction of chromatography equipmentdesign of biotechbiopharmaceutical and plasma manufacturing facilitiesscientific research and evaluationengineering; Design of biotechbiopharmaceutical and plasma manufacturing facilities relevant to the manufacturing of biologics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate
Publications
History of USPTO decisions and trademark events.
54 publications found
CORV
REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
07/07/2021
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
07/01/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
03/23/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/05/2021
PUBO
PUBLISHED FOR OPPOSITION
01/05/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/16/2020
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
11/30/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/26/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/25/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/24/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/24/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/06/2020
GNRT
NON-FINAL ACTION E-MAILED
07/06/2020
CNRT
NON-FINAL ACTION WRITTEN
07/06/2020
LOPT
LETTER OF PROTEST EVIDENCE FORWARDED
06/25/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/12/2020
GNRT
NON-FINAL ACTION E-MAILED
02/12/2020
CNRT
NON-FINAL ACTION WRITTEN
02/12/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
01/28/2020
PBSR
WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST
01/27/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/14/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/14/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/14/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
01/10/2020
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
01/01/2020
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
11/27/2019
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/19/2019
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/19/2019
CNSI
SUSPENSION INQUIRY WRITTEN
11/19/2019
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
11/18/2019
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
10/30/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/18/2019
GNSL
LETTER OF SUSPENSION E-MAILED
05/18/2019
CNSL
SUSPENSION LETTER WRITTEN
05/18/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/16/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/16/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
05/09/2019
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/14/2018
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/14/2018
CNSI
SUSPENSION INQUIRY WRITTEN
11/14/2018
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/09/2018
GNSL
LETTER OF SUSPENSION E-MAILED
05/09/2018
CNSL
SUSPENSION LETTER WRITTEN
05/09/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/09/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/09/2018
ALIE
ASSIGNED TO LIE
05/02/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/24/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/16/2018
GNRT
NON-FINAL ACTION E-MAILED
02/16/2018
CNRT
NON-FINAL ACTION WRITTEN
02/16/2018
DOCK
ASSIGNED TO EXAMINER
02/14/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/14/2017
NWAP
NEW APPLICATION ENTERED
11/07/2017
Continuous trademark protection
Get notified about every new filing that threatens EVOLVE BIOLOGICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.